This study involves patients who have multiple sclerosis or spinal cord injury and are experiencing bladder problems due to overactive bladder muscle, which is a condition where the bladder muscle contracts uncontrollably, leading to urinary incontinence. These patients use a technique called clean intermittent self-catheterization, which means they insert a thin tube into their bladder several times a day to empty it. The study focuses on patients who have bacteria in their urine without experiencing any symptoms, which is called asymptomatic bacteriuria, and who are scheduled to receive injections of botulinum toxin A directly into the bladder to help control the overactive bladder. The medications being studied in this trial include various antibiotics such as amoxicillin, ofloxacin, ceftriaxone, levofloxacin, clavulanic acid, aztreonam, pivmecillinam hydrochloride, trimethoprim, ciprofloxacin, sulfamethoxazole, fosfomycin trometamol, and cefixime.
The purpose of this study is to compare two different approaches to managing the bacteria in the urine before the botulinum toxin injection. One approach involves giving antibiotics around the time of the injection, which is the current standard practice, while the other approach avoids giving antibiotics unless symptoms develop later. The study aims to determine whether avoiding antibiotics initially is just as safe and effective as the standard approach in preventing urinary tract infections that cause symptoms after the injection. A urinary tract infection with symptoms would include signs such as fever, pain during urination, or other clear indicators that the infection is causing problems in the body.
During the study, patients will have their urine tested about five days before the scheduled botulinum toxin injection to check for bacteria. Following the injection, they will be monitored for six weeks to see if they develop a symptomatic urinary tract infection. The study will also track other health events, visits to emergency departments, and unplanned hospital admissions during this period. At the six-week mark, patients will undergo bladder function tests and keep a three-day diary recording how often they need to use catheterization, episodes of urgency, and any incontinence episodes. The study will measure various aspects of bladder function, including bladder capacity and pressure, to assess how well the botulinum toxin treatment is working.



France